Aperture Venture Partners
ActiveVenture Capital
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Aperture Venture Partners.
Key people at Aperture Venture Partners.
Key people at Aperture Venture Partners.
Aperture Venture Partners is a New York-based venture capital firm specializing in early-stage and growth-stage investments primarily within the healthcare and healthtech sectors. Their mission centers on partnering with exceptional entrepreneurs to build innovative companies in medical devices, pharmaceuticals, healthcare IT/services, and diagnostics. Aperture provides both financial capital—typically ranging from $1 million to $5 million per investment—and strategic mentorship to help startups scale and succeed. Their portfolio reflects a strong focus on advancing health and healthy living technologies, contributing significantly to the medical innovation ecosystem[2][3][5].
Founded in 2002, Aperture Venture Partners has evolved into a specialized healthcare investment firm headquartered in New York City. The firm is led by key partners including Managing Partners Eric H. Sillman and Tony Natale, and Senior Partner Thomas P. Cooper, who bring deep industry expertise and a track record of successful investments. Over time, Aperture has refined its focus to early-stage healthtech companies, leveraging its partners’ extensive knowledge to support startups through critical growth phases and exits[3][5].
Aperture Venture Partners rides the accelerating trend of digital transformation and innovation in healthcare, a sector driven by rising demand for improved patient outcomes, cost efficiencies, and technological advancements such as AI, diagnostics, and medical devices. The timing is critical as healthcare systems worldwide seek scalable, tech-enabled solutions. Aperture’s investments help bridge the gap between early innovation and commercial viability, influencing the broader ecosystem by enabling startups to bring disruptive health technologies to market and improve global health standards[1][2][3].
Looking ahead, Aperture Venture Partners is well-positioned to capitalize on ongoing healthcare innovation trends, including personalized medicine, telehealth, and AI-driven diagnostics. Their continued focus on early-stage healthtech companies suggests a pipeline of transformative startups that could redefine healthcare delivery. As regulatory environments evolve and healthcare digitization expands, Aperture’s influence is likely to grow, further shaping the startup ecosystem and contributing to advancements in medical technology and patient care[1][2][3][5].
In summary, Aperture Venture Partners combines deep healthcare expertise, strategic investment, and hands-on support to foster innovation in healthtech, making it a pivotal player in the evolving healthcare venture capital landscape.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jul 1, 2025 | Neuros Medical | $56.0M Series D | — | Amzak Health Investors, EQT Life Sciences, Osage University Partners, Casey Tansey, U.S. Venture Partners |
| Jan 1, 2025 | Sound Blade Medical | $17.0M Series A | — | — |
| Aug 1, 2024 | XII Medical | $45.0M Series B | — | — |
| May 1, 2022 | XII Medical | $30.0M Series A | — | — |
| Jan 1, 2021 | Neuros Medical | $39.0M Series B | — | Amzak Health Investors, EQT Life Sciences, Osage University Partners, Casey Tansey |
| Aug 1, 2017 | Neuros Medical | $20.0M Series A | — | Amzak Health Investors, EQT Life Sciences, Osage University Partners, Casey Tansey, U.S. Venture Partners |
| Dec 1, 2013 | Xlumena | $25.0M Series C | — | Deerfield Management |
| Apr 1, 2011 | Xlumena | $7.0M Series B | — | Deerfield Management |
